Browse by ▼

Krishna Maheshwari

All Posts

  • Buy or Hold This Biopharmaceutical

    By Krishna Maheshwari - August 15, 2012 | Tickers: LLY, MNKD, NKTR, NVO, PFE

    Mannkind (NASDAQ: MNKD) is an inhalable drug company developing a fast acting, inhalable insulin (branded Afrezza) that is superior to any other insulin in the market today and a likely blockbuster drug.  They have completed phase III clinical trials and received no drug efficacy related pushback from the FDA, but have received two CRLs recently.  They are currently conducting two clinical trials to prove that the inhaler they intend to more »

  • Should you Invest in Amazon, Google, or Facebook?

    By Krishna Maheshwari - May 31, 2012 | Tickers: AMZN, EBAY, FB, GOOG, MSFT | Editor's Choice

    Amazon (NASDAQ: AMZN), Google (NASDAQ: GOOG), and Facebook (NASDAQ: FB) have all changed the world since their founding.  They are all growing at amazing rates and in all likelihood have significant growth ahead of them.  However, if you could only invest in one of these three companies, which one should you choose?

    Let's consider a few key factors about these companies and compare them. 

    TTM (2012/2011)

    Amazon

    Google more »

  • Bull Case for Mannkind

    By Krishna Maheshwari - May 24, 2012 | Tickers: ALKS, LLY, MNKD, NVO, PFE

    Mannkind (NASDAQ: MNKD) is a multi-bagger from its current levels in the next 1-3 years.

    This article will dive into the key elements of the investment thesis behind why I think Mannkind has such an enomous potential and will also highlight some of the risks.  As a summary, we have a serial entrepreneur with multiple successes in the CEO.  The drug has gone through Phase III clinical trials with no more »